Management of Severe Hyperglycemia

Initial Assessment and Management

The American Diabetes Association recommends evaluating patients for signs of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), including mental status changes, dehydration, fruity breath odor, abdominal pain, nausea/vomiting 1
The American Diabetes Association suggests obtaining laboratory tests including complete metabolic panel, serum ketones, arterial blood gas (if DKA suspected), and urinalysis to assess the severity of hyperglycemia 1
The American Diabetes Association recommends initiating fluid resuscitation to restore circulatory volume and tissue perfusion, and correct electrolyte imbalances, particularly potassium 1

The American College of Endocrinology recommends initiating continuous intravenous insulin infusion with a target glucose range of 140-180 mg/dL for patients with critical hyperglycemia 2, 3
The American Diabetes Association suggests administering insulin based on validated written or computerized protocols that allow for predefined adjustments in the infusion rate, accounting for glycemic fluctuations 4
The American Diabetes Association recommends monitoring blood glucose frequently (every 30 min to 2 hours) during IV insulin therapy to prevent hypoglycemia and hyperglycemia 4

The European Association for the Study of Diabetes recommends transitioning to subcutaneous insulin once the patient is stable with glucose levels consistently below 200 mg/dL 5
The American Diabetes Association suggests administering basal insulin 2-4 hours before discontinuing IV insulin to prevent rebound hyperglycemia 1
The International Diabetes Federation recommends implementing a basal-bolus insulin regimen for patients with severe hyperglycemia (>300 mg/dL) 5
The American Diabetes Association suggests calculating the total daily dose of insulin at 0.3-0.5 units/kg and distributing it as 50% basal insulin and 50% prandial insulin 5

For a patient with severe hyperglycemia (RBS 500 mg/dL), the American College of Endocrinology recommends starting with basal insulin (glargine or detemir) at 0.2-0.25 units/kg once daily 5
The American Diabetes Association suggests adding prandial rapid-acting insulin (lispro, aspart, or glulisine) before meals at 0.1-0.15 units/kg divided into three doses 3, 5
The European Association for the Study of Diabetes recommends providing correction doses with rapid-acting insulin for persistent hyperglycemia 3

The American Diabetes Association recommends monitoring blood glucose before meals and at bedtime to assess glycemic control 4
The International Diabetes Federation suggests adjusting insulin doses daily based on blood glucose patterns 3
The American College of Endocrinology recommends scheduling follow-up within 1-2 weeks to reassess glycemic control 1

The American Diabetes Association recommends considering adding metformin as first-line therapy if not contraindicated to prevent recurrence of severe hyperglycemia 6, 7
The European Association for the Study of Diabetes suggests considering additional oral agents or continued insulin therapy based on the severity of diabetes for patients with persistent hyperglycemia despite metformin 6, 7
The American Diabetes Association recommends providing diabetes self-management education to prevent future episodes of severe hyperglycemia 1

The American College of Endocrinology recommends avoiding the use of sliding scale insulin alone without basal insulin, as this approach is ineffective and discouraged 3
The American Diabetes Association suggests being vigilant for hypoglycemia, which is a common adverse event with insulin therapy, although the specific reference for this statement is not provided
The International Diabetes Federation recommends considering maintaining insulin therapy long-term along with oral agents for patients with very high HbA1c (>10%) 7